Pfizer has appointed Cecile Guegan, currently Senior Vice President, Finance, Global Biopharmaceutical Business, as Interim Chief Financial Officer (CFO), effective 16 August.
Dave Denton, Executive Vice President and CFO, will step down from his current role and leave the company on 15 August for a professional opportunity outside the pharmaceutical industry. Denton and Guegan will work together to ensure a seamless transition while Pfizer conducts a comprehensive internal and external search.
Guegan brings more than two decades of experience at Pfizer, amassing deep global financial experience leading finance across a wide range of complex and strategic portfolios, research and development, and several regions. In her current role, she is directly responsible for the financial operations and reporting of Pfizer’s biopharmaceutical business across all therapeutic areas and geographies. She has strong financial judgement and a proven track record of leading important enterprise initiatives, including the integration of Seagen into Pfizer in 2024.
Albert Bourla, Chairman and CEO at Pfizer, said: “Given Cecile’s deep institutional knowledge and financial acumen, I have every confidence in her ability to lead Pfizer’s finance organisation and keep us focused on what matters most – executing our strategy and delivering for patients and shareholders.
“We wish Dave the very best. He has been a steady and trusted steward of Pfizer’s financial health, and we are grateful for his leadership.”
Denton said: “It has been an honour and a privilege to work alongside Albert. Pfizer is in excellent hands, and I leave knowing the executive leadership team, now including Cecile as interim CFO, will continue to succeed and carry its important work forward.”